What question did this study set out to answer?

To evaluate the efficacy and safety of pharmacokinetic-guided busulfan-melphalan conditioning in autologous stem cell transplantation for relapsed DLBCL.

December 8, 2025BloodOpen Access

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

CSColin C. StewartOntario Institute for Cancer Research KHKevin A. HayOccupational Cancer Research Centre MDMichelle Dowhan

Discussion

Member takes

Implication

Retrospective analysis indicates improved progression-free survival in DLBCL with pharmacokinetic-guided transplant regimen, suggesting BuMel is a viable alternative to BEAM.

Key Points

To evaluate the efficacy and safety of pharmacokinetic-guided busulfan-melphalan conditioning in autologous stem cell transplantation for relapsed DLBCL.
Retrospective single-centre study of patients ≥18 years undergoing R-BuMel ASCT for relapsed DLBCL from 2012 to 2024.
Pharmacokinetic monitoring of busulfan dosing was conducted for optimal dosing adjustments during treatment.
Primary outcomes included progression-free survival (PFS) and overall survival (OS) post-ASCT.
Median progression-free survival was 2.6 years; overall survival was 3.8 years over median follow-up of 2.8 years.
Inferior PFS associated with primary refractory disease and higher International Prognostic Index scores.
Toxicities included febrile neutropenia in 80% of patients but no pneumonitis or veno-occlusive disease.

Cite This Study

Stewart et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db7c https://doi.org/10.1182/blood-2025-2761

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis indicates improved progression-free survival in DLBCL with pharmacokinetic-guided transplant regimen, suggesting BuMel is a viable alternative to BEAM.

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider